AR045878A2 - Uso de copuestos de sulfonamidas - Google Patents
Uso de copuestos de sulfonamidasInfo
- Publication number
- AR045878A2 AR045878A2 ARP040104466A ARP040104466A AR045878A2 AR 045878 A2 AR045878 A2 AR 045878A2 AR P040104466 A ARP040104466 A AR P040104466A AR P040104466 A ARP040104466 A AR P040104466A AR 045878 A2 AR045878 A2 AR 045878A2
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- amino
- dialkylamino
- alkylamino
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
Abstract
El presente se refiere al uso de compuestos sulfonamidas de fórmula general (1), en donde: Z significa un grupo de fenilo sustituido, piridilo sustituido, primidilo sustituido o indolilo sustituido del grupo de fórmulas (2), R1 significa hidrógeno, amino, alquilamino inferior, dialquilamino inferior, alquilo inferior, halógeno o trifluorometilo; R2 significa hidrógeno o alquilo inferior; R3 significa hidrógeno, amino, alquilamino inferior, dialquilamino inferior, alquilo inferior, CF3, alcoxilo inferior o halógeno; R4 significa amino, alquilamino inferior, dialquilamino inferior, alquilo inferior, alcoxilo inferior o halógeno; R5 significa hidrógeno, alquilamino inferior, dialquilamino inferior, alcoxilo inferior o halógeno; R6 significa alquilo inferior, alquilamino inferior, dialquilamino inferior, alcoxilo inferior, halógeno o CF3; R7 significa amino, alquilamino inferior, dialquilamino inferior, alcoxilo inferior, alquilsulfanilo inferior, mercapto, pirrolidin-1-ilo o azetidin-1-ilo; R8 significa amino, alquilamino inferior, dialquilamino inferior, bencil-amino, alcoxilo inferior, alquilsulfanilo inferior, halógeno, pirrolidin-1ilo o azetidin-1-ilo; R9 y R10 significan cada uno, independientemente, alcoxilo inferior o alquil-amino inferior; R11 significa hidrógeno o halógeno; R12 significa hidrógeno o alquilo inferior; y a significa un doble enlace opcional, con la salvedad de que R7 y R8 no significan simultáneamente metoxilo; así como sus sales farmacéuticamente aceptables, para la producción de medicamentos que contienen los compuestos de fórmula general (1) como sustancias terapéuticamente activas contra trastornos del sistema nervioso central.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96110462 | 1996-06-28 | ||
| EP97105363 | 1997-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045878A2 true AR045878A2 (es) | 2005-11-16 |
Family
ID=26142037
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970102809A AR007617A1 (es) | 1996-06-28 | 1997-06-26 | Compuestos de sulfonamidas, un medicamento que contiene a dichos compuestos y un procedimiento para la preparacion de los mismos. |
| ARP040104466A AR045878A2 (es) | 1996-06-28 | 2004-12-01 | Uso de copuestos de sulfonamidas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970102809A AR007617A1 (es) | 1996-06-28 | 1997-06-26 | Compuestos de sulfonamidas, un medicamento que contiene a dichos compuestos y un procedimiento para la preparacion de los mismos. |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US5939451A (es) |
| EP (1) | EP0815861B1 (es) |
| JP (1) | JP3032176B2 (es) |
| KR (1) | KR100260480B1 (es) |
| CN (1) | CN1086578C (es) |
| AR (2) | AR007617A1 (es) |
| AT (1) | ATE205714T1 (es) |
| AU (1) | AU694696B2 (es) |
| BR (1) | BR9703788A (es) |
| CA (1) | CA2209018C (es) |
| CO (1) | CO4900073A1 (es) |
| CZ (1) | CZ9702002A3 (es) |
| DE (1) | DE59704640D1 (es) |
| DK (1) | DK0815861T3 (es) |
| ES (1) | ES2163071T3 (es) |
| HK (1) | HK1007865A1 (es) |
| HR (1) | HRP970349B1 (es) |
| HU (1) | HUP9701096A3 (es) |
| IL (1) | IL121141A (es) |
| MA (1) | MA24237A1 (es) |
| MX (1) | MX9704817A (es) |
| NO (1) | NO972983L (es) |
| NZ (1) | NZ328146A (es) |
| PL (1) | PL320822A1 (es) |
| PT (1) | PT815861E (es) |
| RU (1) | RU2192257C2 (es) |
| SG (1) | SG77139A1 (es) |
| TR (1) | TR199700550A2 (es) |
| YU (1) | YU27697A (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| KR20010021643A (ko) * | 1997-07-11 | 2001-03-15 | 피터 기딩스 | 5-ｈｔ6수용체길항제인술폰아미드유도체및그의제조방법 |
| GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| US6133287A (en) * | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
| US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| US6686374B1 (en) * | 1999-08-12 | 2004-02-03 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
| US6399617B1 (en) | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
| SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
| US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
| DE10053813A1 (de) * | 2000-10-30 | 2002-05-08 | Bayer Ag | Neue Verwendung von Sulfonamiden |
| ITBO20010271A1 (it) * | 2001-05-08 | 2002-11-08 | Giuseppe Cannazza | Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl |
| CA2443724C (en) * | 2001-05-11 | 2009-11-03 | Patrizia Caldirola | Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
| US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| WO2002100822A1 (en) * | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| ATE323680T1 (de) * | 2002-02-13 | 2006-05-15 | Glaxo Group Ltd | 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen |
| WO2003068732A2 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds |
| AU2003213184A1 (en) * | 2002-02-22 | 2003-09-09 | Pharmacia And Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
| EP1897881A3 (en) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
| JP4754821B2 (ja) | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物 |
| US6989399B2 (en) | 2002-08-01 | 2006-01-24 | Bristol-Myers Squibb Company | Antiamyloid phenylsulfonamides: N-alkanol derivatives |
| US7288538B2 (en) | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
| CA2515780C (en) * | 2003-02-20 | 2012-12-11 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| ES2222829B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222830B1 (es) | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222827B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222832B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| KR100793095B1 (ko) * | 2003-10-01 | 2008-01-10 | 주식회사 프로메디텍 | Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체 |
| SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| KR20060101772A (ko) * | 2003-12-19 | 2006-09-26 | 화이자 인코포레이티드 | 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-ｈｓｄ-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물 |
| MX2007003545A (es) * | 2004-09-30 | 2007-05-18 | Hoffmann La Roche | Composiciones y metodos para tratar trastornos cognitivos. |
| EP1676841A1 (en) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
| GB0518667D0 (en) | 2005-09-13 | 2005-10-19 | Univ Reading The | Method |
| FI20055498A0 (fi) * | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
| WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| JPWO2008114831A1 (ja) * | 2007-03-20 | 2010-07-08 | 国立大学法人 岡山大学 | スルホンアミド基を有する抗菌剤 |
| WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| CN101591327B (zh) * | 2008-05-26 | 2012-07-25 | 华东理工大学 | 苯烷酰胺类化合物及其用途 |
| US9029545B2 (en) * | 2009-12-18 | 2015-05-12 | Glaxosmithkline Intellectual Property Limited | Thienopyridine NOX2 inhibitors |
| US20150291517A1 (en) * | 2012-11-28 | 2015-10-15 | Martijn Fiers | Benzenesulfonamide compounds for somatic embryogenesis in plants |
| US20170360726A1 (en) * | 2014-12-05 | 2017-12-21 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| EP3412652A1 (en) * | 2017-06-06 | 2018-12-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of rac1 and uses thereof for treating cancers |
| EP3412651A1 (en) * | 2017-06-06 | 2018-12-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of rac1 and uses thereof for inducing bronchodilatation |
| CN115703722B (zh) * | 2021-08-03 | 2024-06-25 | 江苏国泰超威新材料有限公司 | 一种n,n-二甲基三氟甲基磺酰胺的制备方法 |
| CN118108676B (zh) * | 2024-03-01 | 2025-02-07 | 中国药科大学 | 苯磺酰胺类化合物、其药物组合物及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2192490A (en) * | 1936-03-21 | 1940-03-05 | Hoffmann La Roche | Derivatives of 4-aminobenzenesulphonamides and process for the manufacture of same |
| NL127990C (es) * | 1962-12-29 | |||
| FR1383287A (fr) * | 1962-12-29 | 1964-12-24 | Chugai Pharmaceutical Co Ltd | Procédé de production de 4-sulfanilamidopyrimidines |
| DE3834704A1 (de) * | 1988-10-07 | 1990-06-07 | Schering Ag | Fluorsubstituierte benzolderivate |
| JPH04202173A (ja) * | 1990-11-30 | 1992-07-22 | Zeria Pharmaceut Co Ltd | スルホンアミド誘導体及びそれを含有する５―リポキシゲナーゼ阻害剤 |
| ATE231723T1 (de) * | 1991-02-22 | 2003-02-15 | Howard K Shapiro | Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe |
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
-
1997
- 1997-06-04 US US08/869,063 patent/US5939451A/en not_active Expired - Fee Related
- 1997-06-19 AT AT97109984T patent/ATE205714T1/de not_active IP Right Cessation
- 1997-06-19 EP EP97109984A patent/EP0815861B1/de not_active Expired - Lifetime
- 1997-06-19 DE DE59704640T patent/DE59704640D1/de not_active Expired - Fee Related
- 1997-06-19 ES ES97109984T patent/ES2163071T3/es not_active Expired - Lifetime
- 1997-06-19 DK DK97109984T patent/DK0815861T3/da active
- 1997-06-19 PT PT97109984T patent/PT815861E/pt unknown
- 1997-06-20 SG SG1997002115A patent/SG77139A1/en unknown
- 1997-06-20 NZ NZ328146A patent/NZ328146A/en unknown
- 1997-06-23 IL IL12114197A patent/IL121141A/en not_active IP Right Cessation
- 1997-06-24 JP JP9167060A patent/JP3032176B2/ja not_active Expired - Fee Related
- 1997-06-25 CZ CZ972002A patent/CZ9702002A3/cs unknown
- 1997-06-25 HU HU9701096A patent/HUP9701096A3/hu unknown
- 1997-06-26 HR HR970349A patent/HRP970349B1/xx not_active IP Right Cessation
- 1997-06-26 NO NO972983A patent/NO972983L/no unknown
- 1997-06-26 CO CO97035749A patent/CO4900073A1/es unknown
- 1997-06-26 CA CA002209018A patent/CA2209018C/en not_active Expired - Fee Related
- 1997-06-26 MX MX9704817A patent/MX9704817A/es not_active IP Right Cessation
- 1997-06-26 AR ARP970102809A patent/AR007617A1/es active IP Right Grant
- 1997-06-27 TR TR97/00550A patent/TR199700550A2/xx unknown
- 1997-06-27 MA MA24694A patent/MA24237A1/fr unknown
- 1997-06-27 PL PL97320822A patent/PL320822A1/xx unknown
- 1997-06-27 YU YU27697A patent/YU27697A/sh unknown
- 1997-06-27 RU RU97110875/14A patent/RU2192257C2/ru not_active IP Right Cessation
- 1997-06-27 AU AU28416/97A patent/AU694696B2/en not_active Ceased
- 1997-06-27 CN CN97113553A patent/CN1086578C/zh not_active Expired - Fee Related
- 1997-06-28 KR KR1019970028527A patent/KR100260480B1/ko not_active IP Right Cessation
- 1997-06-30 BR BR9703788A patent/BR9703788A/pt not_active Application Discontinuation
-
1998
- 1998-06-03 US US09/089,705 patent/US5932599A/en not_active Expired - Fee Related
- 1998-06-03 US US09/089,632 patent/US6030976A/en not_active Expired - Fee Related
- 1998-06-03 US US09/089,706 patent/US5998665A/en not_active Expired - Fee Related
- 1998-07-07 HK HK98108915A patent/HK1007865A1/xx not_active IP Right Cessation
-
2004
- 2004-12-01 AR ARP040104466A patent/AR045878A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045878A2 (es) | Uso de copuestos de sulfonamidas | |
| ES2111650T3 (es) | Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p. | |
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| GEP20074244B (en) | Compounds that modulate ppar activity and methods for their preparation | |
| ECSP045229A (es) | Piridinonas sustituidas como moduladores de la p38 map quinasa | |
| AR240929A2 (es) | "n-piridinsulfonil-n'-piridinil-y-triazinil-ureas procedimiento parasu preparacion, intermediarios para uso exclusivo en dicho procedimiento, y composiciones que contienen dichas ureas" | |
| PE20020720A1 (es) | Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa | |
| AR036075A1 (es) | Compuestos derivados de pirimidina,triazina,y,pirazina,su uso, un procedimiento para su preparacion y medicamentos que los comprenden | |
| TR200200351T2 (tr) | Yoğunlaştırılmış indolin türevleri, bunların 5HT, özellikle 5HT2C, reseptör ligandları olarak kullanımı | |
| AR029454A1 (es) | Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos | |
| AR034423A1 (es) | Imidazotriazinonas sustituidas, un procedimiento para su preparacion, medicamentos y el uso de dichas imidazotriazinonas para la preparacion de medicamentos | |
| NO985599L (no) | Arylsubstituerte, sykliske aminer som selektive dopamin D3-ligander | |
| AR028817A1 (es) | Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen | |
| AR008291A1 (es) | Derivados de tetrahidroisoquinolina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso para la preparacionde un medicamento. | |
| CO4840509A1 (es) | 2,4 diaminopirimidinas sustituidas, medicamento que contiene dichos compuestos para el control o la prevencion de enfermedades infecciosas y procedimiento para la preparacion de dichos compuestos" | |
| SE9702563D0 (sv) | Compounds | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
| UY26988A1 (es) | Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos. | |
| AR027134A1 (es) | Derivados de indol. | |
| CR6968A (es) | Un nuevo compuesto derivado de la triptamina y sus analogos. | |
| ES2172376B1 (es) | Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| NO20065696L (no) | Piperazinderivater av alkyloksindoler som 5-HT7 reseptoraktive midler. | |
| CO4930268A1 (es) | BENZO[e]ISOINDOLES Y BENZO[h]ISOQUINOLINAS TRICICLICOS | |
| CR6503A (es) | Derivados de- 1-trifluorometil-4-hidroxi-7-piperidinil-aminometiclcromano | |
| ECSP972166A (es) | Sulfonamidas y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |